Canada markets open in 2 hours 2 minutes

Brainstorm Cell Therapeutics Inc. (BCLI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.5250-0.0151 (-2.80%)
At close: 04:00PM EDT
0.5000 -0.02 (-4.76%)
Pre-Market: 05:05AM EDT

Brainstorm Cell Therapeutics Inc.

1325 Avenue of Americas
28th Floor
New York, NY 10019
United States
201 488 0460
https://www.brainstorm-cell.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 29

Key Executives

NameTitlePayExercisedYear Born
Mr. Chaim LebovitsPresident & Co-CEO878.78kN/A1971
Dr. Stacy R. Lindborg Ph.D.Co-Chief Executive Officer751.08kN/A1971
Dr. Irit Arbel DSc, Ph.D.Co-Founder & Independent Vice Chair of the BoardN/AN/A1960
Ms. Alla Patlis CPA, M.B.A.Interim CFO & Controller130.92kN/A1987
Mr. Uri YablonkaExecutive VP, Chief Business Officer, Secretary & Director247.06kN/A1977
Dr. Daniel Offen Ph.D.Chief Scientific AdvisorN/AN/AN/A
Ms. Mary Kay TurnerSenior Vice President of Patient Advocacy & Government AffairsN/AN/AN/A
Dr. Ibrahim Dagher M.D.Executive VP & Chief Medical OfficerN/AN/A1969
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

Corporate Governance

Brainstorm Cell Therapeutics Inc.’s ISS Governance QualityScore as of April 1, 2024 is 4. The pillar scores are Audit: 9; Board: 3; Shareholder Rights: 2; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.